Trials / Terminated
TerminatedNCT01490775
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib)Therapy
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Rex Cancer Center, Raleigh, NC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.
Detailed description
This is a randomized, controlled pilot study to introduce eMedonline telemonitoring technology to CML patients taking Gleevec or Tasigna. eMedonline will be used to automatically collect time-dose specific medication data for individual patients, including dosing times, missed doses, adverse events and e-diary data. All data will be available to research staff for remote review via Web interface. Adverse events and non-adherence will prompt interventions including supportive care counseling.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | no access to eMedonline | patients will be followed for 3 months but will not use eMedonline |
| BEHAVIORAL | eMedonline access | patients will be given access to eMedonline use for 3 months |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2015-02-12
- Completion
- 2015-06-30
- First posted
- 2011-12-13
- Last updated
- 2018-08-13
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01490775. Inclusion in this directory is not an endorsement.